Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Results 1 - 20 of 21 : 1 2 Next »

Recs

0
Member Avatar craze191st (80.89) Submitted: 10/5/2014 2:19:22 PM : Outperform Start Price: $2.23 IDRA Score: +69.15

Top notch management and 3rd generation anti-sense technology is sure to be hit.

Recs

0
Member Avatar SmartAce (99.88) Submitted: 8/28/2014 10:17:41 AM : Underperform Start Price: $2.86 IDRA Score: -32.31

It's easier to fool people than to convince them that they have been fooled.
Twain

Recs

1
Member Avatar csims2007 (< 20) Submitted: 10/24/2013 10:37:11 AM : Outperform Start Price: $2.45 IDRA Score: +39.97

I got in at 1.65 just over a month ago this stock has room to run!

Recs

0
Member Avatar chris293 (86.58) Submitted: 9/17/2013 9:30:45 PM : Outperform Start Price: $1.92 IDRA Score: +81.11

DNA, RNA, or parts of are working on mice anyway. Recently read where the memories of say mice were restored. You never know what the future will bring.

Recs

3
Member Avatar zzlangerhans (99.84) Submitted: 5/24/2013 12:17:29 PM : Underperform Start Price: $0.69 IDRA Score: -440.58

Idera currently has two big strikes against them. One is a lengthy string of pipeline failures related to both efficacy and safety issues, despite the appearance of having a powerful technical platform in the field of toll-like receptors. Despite their failures and destrutction of shareholder value, the company declined to bow out gracefully the way companies like Altus and Aryx did in similar circumstances. This brings us to the second strike, which is a heavy use of dilutive financing including preferred stock and ITM warrants. Although Yahoo Finance lists the current share count as 28M, my count of all shares including preferred and ITM warrants is 81M. That gives a true market cap of 60M, which is still puny but also undeserved given the low likelihood that the company won't dilute again before topline data from the phase II trial of IMO-8400 in psoriasis, which hasn't even begun yet. If that trial fails like so many of Idera's prior efforts, that's three strikes and out.

Recs

1
Member Avatar ExtremesTracker (60.46) Submitted: 12/7/2010 6:11:40 PM : Outperform Start Price: $2.45 IDRA Score: -10.17

picks source: zzlangerhans
as of 12/7/2010, these were the 5 most underperformed designated "top picks" by zz. these are the 5 picks (out 7 top picks):
alny,idra,rtix,biod,bdsi
No due diligence performed, these are hail marys that atleast a couple may possibly be insane multi baggers potentially
Very risky.

Recs

2
Member Avatar BillyTG (29.26) Submitted: 10/21/2010 10:50:32 AM : Outperform Start Price: $2.91 IDRA Score: -41.02

rfaramir follow on zzlangerhan's follow on portefeuille's rec of his rec

Recs

0
Member Avatar chicachick (73.45) Submitted: 10/12/2010 3:48:03 PM : Outperform Start Price: $3.01 IDRA Score: -48.12

Bravobevo

Recs

0
Member Avatar LongShortIndex (30.79) Submitted: 7/6/2010 4:45:02 AM : Outperform Start Price: $3.53 IDRA Score: -90.27

medical/biotech related picks - 4 buys / 4 sells
BUY:exel,idra,rtix,dcth
SELL:pbth,pcyc,vrtx,nbix

Recs

0
Member Avatar Bumkinpops (< 20) Submitted: 5/9/2010 11:44:00 AM : Outperform Start Price: $4.89 IDRA Score: -98.47

Technology platform with great potential.

Recs

0
Member Avatar pjani06 (29.26) Submitted: 3/25/2010 1:20:41 AM : Outperform Start Price: $5.65 IDRA Score: -107.78

stock picks with the potential of being doublers to multibaggers, yet risky, very risky and can go nearly to 0. hated by CAPs, but they have atleast 1 CAPs allstar that I like that has greenthumbed this one. These things have been beaten, and if 2 of 6 of em double, and another 2 don't even move, well it makes up if the last 2 go to zero n basically tank.
DMAN, FSLR, IDRA, ARQL, OSIR, MDVN

Recs

1
Member Avatar ScreenerStizBear (83.21) Submitted: 6/26/2008 2:26:22 PM : Underperform Start Price: $14.63 IDRA Score: +140.05

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recs

0
Member Avatar goldnrtrvrlvr (< 20) Submitted: 5/5/2008 7:24:39 AM : Outperform Start Price: $14.75 IDRA Score: -126.82

New Hi

Recs

0
Member Avatar fouadtawfig (< 20) Submitted: 4/16/2008 11:27:35 AM : Outperform Start Price: $13.03 IDRA Score: -129.94

exiting patents needed for farmuecitical market will reflect son expanded orders and deman for larger supply.

Recs

0
Member Avatar mbeleza (< 20) Submitted: 11/14/2007 5:56:55 AM : Underperform Start Price: $12.15 IDRA Score: +114.25

It´s at it's most

Recs

0
Member Avatar eXigy (32.76) Submitted: 9/5/2007 2:59:30 PM : Underperform Start Price: $8.80 IDRA Score: +104.45

Not a long-termie, because I'm not personally well into the stock and cannot tell whether they have something unique in their safes to take it out by Easter or not.
But I can tell a stock with such stats and such current price is to go down.

Recs

0
Member Avatar fire0821 (< 20) Submitted: 6/21/2007 10:12:51 PM : Outperform Start Price: $6.87 IDRA Score: -88.05

pharmaceuticals are always fluctuating up and down according to the seasons. summer is a down season.

Recs

0
Member Avatar TyPicks (< 20) Submitted: 2/8/2007 11:02:07 AM : Outperform Start Price: $9.40 IDRA Score: -111.79

Wall Street Pro Pick.

Recs

0
Member Avatar davezzzz (25.26) Submitted: 1/26/2007 7:51:21 PM : Outperform Start Price: $7.67 IDRA Score: -104.76

Hey - it's just a random pick from the top performers list. What do I know? (not much)

Recs

1
Member Avatar lemapud (< 20) Submitted: 1/22/2007 5:20:24 PM : Outperform Start Price: $7.70 IDRA Score: -104.87

IDERA has cutting edge new science in the field of immunology. They have had their share of followers and detractors over the years, and survived through it all. They have a strong company plan now, good partners, and exciting therapies that will be used to combat aids, cancer, and other human maladies. Above all IDERA has always been an honest, intelligent company that had strived to make a difference in health and science.

Results 1 - 20 of 21 : 1 2 Next »

Featured Broker Partners


Advertisement